Extended Data Fig. 2: GSK-626616-inhibited DYRK3 localizes to stress granules and forms mitotic granules. | Nature

Extended Data Fig. 2: GSK-626616-inhibited DYRK3 localizes to stress granules and forms mitotic granules.

From: Kinase-controlled phase transition of membraneless organelles in mitosis

Extended Data Fig. 2

a, Western blot shows the expression level of endogenous DYRK3 and EGFP–DYRK3 in HeLa-FlpIn-Trex cells stably expressing inducible EGFP–DYRK3(WT). EGFP–DYRK3 expression was induced with doxycycline (500 ng ml−1, 4 h). The same induction conditions were used for Fig. 1c–e and Extended Data 2b. b, Colocalization of GSK-626616-inhibited (1 μM, 2 h) EGFP–DYRK3(WT) with stress granules upon arsenite treatment (500 μM, 45 min). c, Mitotic cells show formation of small DYRK3-positive granules upon GSK-626616 treatment (1 μM, 1 h). d, Phosphoproteomic data of the human cell cycle showing changes in the regulated phospho-sites that are associated with the DYRK3-specific interactors detected in Fig. 1a. The majority (74.4%) of these phospho-sites reached peak levels at mitosis. The phospho-site occupancy level is displayed for those sites that were downregulated upon GSK-626616 inhibitor treatment as previously reported9. The phosphoproteomic data were retrieved from a previously published work37. The known localization (splicing speckle, stress granule or centrosome) of the corresponding protein is indicated for each phospho-site. Images and western blots are representative of at least three independent experiments. Scale bars, 10 μm.